Dorocubicel

DB19448ApprovedCell transplant therapies

Dorocubicel is a preparation of UM171-expanded cord-derived allogeneic HSCs used alongside unexpanded CD34-negative HSCs for the treatment of hematopoietic cancers in patients for whom other types of suitable donor cells are not available. Dorocubicel is a preparation of cryopreserved allogeneic umbilical cord-derived hematopoietic stem cells and blood progenitors expanded ex vivo using UM-171.

Mechanism
Curator reviewed · 4 references
Primary indication
Dorocubicel is an active ingredient in Zemcelpro, a cryopreserved allogeneic hematopoietic stem and progenitor cell therapy indicated for the treatment of adult patients with hematological malignancies requiring an allogeneic hematopoietic stem cell transplantation following myeloablative...Curator reviewed · 1 structured indication
Also known as
Allogeneic human umbilical cord blood expanded with UM-171
Code names
ECT-001-CB-DP1

Resolves to

What you can answer from here — as of October 21, 2025

1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Dorocubicel, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.

Create Account